Click Therapeutics’ CT-132 for Migraine Relief Earns FDA’s Breakthrough Device Designation

A new breakthrough device designation from the FDA will bring an advancement in migraine relief to those suffering from the debilitating condition. Following the agency’s BD go-ahead, Click Therapeutics' digital program for treating episodic migraine, called CT-132, will be on an accelerated track to vie for eventual authorization...